Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
Incyte has been named among the top five biotech and pharma employers by Science magazine for the seventh consecutive year, ranking third in 2024. The company was specifically recognized for its commitment to employee respect, social responsibility, and employee loyalty.
Additionally, Incyte received recognition from Newsweek as one of America's 100 Most Loved Workplaces and Most Loved Global Workplaces. These accolades highlight the company's dedication to fostering innovation, growth, and passion within its workforce. The complete Science magazine Top Employers survey and rankings will be featured in the October 25, 2024 print issue.
Incyte è stata nominata tra i primi cinque datori di lavoro nel settore biotech e farmaceutico dalla rivista Science per il settimo anno consecutivo, classificandosi al terzo posto nel 2024. L'azienda è stata specificamente riconosciuta per il suo impegno nel rispetto dei dipendenti, nella responsabilità sociale e nella lealtà verso i lavoratori.
Inoltre, Incyte ha ricevuto un riconoscimento da Newsweek come una delle 100 Aziende più amate in America e nei luoghi di lavoro globali. Questi riconoscimenti evidenziano la dedizione dell'azienda alla promozione dell'innovazione, della crescita e della passione all'interno della sua forza lavoro. L'indagine completa sui più importanti datori di lavoro della rivista Science e le relative classifiche saranno presentate nel numero cartaceo del 25 ottobre 2024.
Incyte ha sido nombrada entre los cinco mejores empleadores de biotech y farmacéutica por la revista Science por séptimo año consecutivo, ocupando el tercer lugar en 2024. La compañía fue reconocida específicamente por su compromiso con el respeto a los empleados, la responsabilidad social y la lealtad hacia los trabajadores.
Además, Incyte recibió reconocimiento de Newsweek como uno de los 100 Lugares de Trabajo Más Amados en América y en el ámbito global. Estos galardones destacan la dedicación de la empresa a fomentar la innovación, el crecimiento y la pasión dentro de su fuerza laboral. La encuesta completa de los Mejores Empleadores de la revista Science y sus clasificaciones se presentarán en la edición impresa del 25 de octubre de 2024.
인사이트는 사이언스 매거진에서 7년 연속 생명공학 및 제약 산업의 상위 5대 고용주로 선정되어 2024년에는 3위를 기록했습니다. 이 회사는 직원 존중, 사회적 책임 및 직원 충성도에 대한 헌신으로 특히 인정받았습니다.
또한 인사이트는 뉴스위크로부터 미국에서 가장 사랑받는 100대 직장 및 전 세계에서 가장 사랑받는 직장 중 하나로 인정받았습니다. 이러한 공로는 기업이 직원 내에서 혁신, 성장 및 열정을 촉진하기 위해 노력하고 있음을 강조합니다. 사이언스 매거진의 최고의 고용주에 대한 전체 설문 조사와 순위는 2024년 10월 25일자 인쇄본에 실릴 예정입니다.
Incyte a été nommée parmi les cinq meilleurs employeurs de biotechnologie et de pharmacie par la revue Science pour la septième année consécutive, se classant au troisième rang en 2024. L'entreprise a été spécifiquement reconnue pour son engagement envers le respect des employés, la responsabilité sociale et la loyauté des employés.
De plus, Incyte a été récompensée par Newsweek comme l'un des 100 lieux de travail les plus appréciés d'Amérique et l'un des lieux de travail les plus appréciés au niveau mondial. Ces distinctions soulignent le dévouement de l'entreprise à encourager l'innovation, la croissance et la passion au sein de sa main-d'œuvre. L'enquête complète sur les meilleurs employeurs de la revue Science et les classements seront présentés dans le numéro papier du 25 octobre 2024.
Incyte wurde zum siebten Mal in Folge von der Zeitschrift Science unter die fünf besten Biotech- und Pharmabetriebe gewählt und belegte 2024 den dritten Platz. Das Unternehmen wurde insbesondere für sein Engagement für den Respekt der Mitarbeiter, soziale Verantwortung und Loyalität gegenüber den Angestellten anerkannt.
Darüber hinaus erhielt Incyte von Newsweek die Auszeichnung als einer der 100 meistgeschätzten Arbeitsplätze in Amerika sowie als der meistgeschätzte globale Arbeitsplatz. Diese Auszeichnungen unterstreichen das Engagement des Unternehmens zur Förderung von Innovation, Wachstum und Begeisterung innerhalb seiner Belegschaft. Die vollständige Umfrage zu den Top-Arbeitgebern der Zeitschrift Science und die entsprechenden Rankings werden in der Printausgabe vom 25. Oktober 2024 veröffentlicht.
- None.
- None.
Recognition Among Several Workplace Awards Received by the Company this Year
In addition to this recognition, earlier this year Incyte was also named one of America’s 100 Most Loved Workplaces and one of the Most Loved Global Workplaces by Newsweek. These honors reflect Incyte’s continued commitment to fostering innovation, growth and passion from within.
“Incyte is honored to be recognized once again as a top employer by Science. This distinction speaks to our commitment to creating an environment where collaboration, mutual respect and a shared passion for science and patients are at the forefront,” said Paula Swain, Executive Vice President, Human Resources, Incyte. “For more than two decades, we have championed a culture that drives innovation, empowering our team to tackle new areas of drug discovery and development, fueled by our drive to Solve On. for patients. Being recognized as great workplaces by Science magazine, as well as other prominent industry publications like Newsweek, reinforces the passion and enthusiasm that motivate us individually and collectively every day.”
The complete Science magazine Top Employers survey feature, along with individual company rankings will be included in the October 25, 2024, print issue of Science and is available now online here: https://www.science.org/content/article/top-20-2024-who-did-science-readers-select-best-biopharma
About Incyte
Incyte is a
For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241024009669/en/
Media
media@incyte.com
Source: Incyte
FAQ
What ranking did Incyte (INCY) receive in Science magazine's 2024 Top Employers List?
How many consecutive years has Incyte (INCY) been in Science magazine's top 5 employers?
What other workplace awards did Incyte (INCY) receive in 2024?